Cormedix Drug Patent Portfolio

Cormedix owns 1 orange book drug protected by 4 US patents Given below is the list of Cormedix's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11738120 Synthesis of taurolidine, purity profiles and polymorphs 15 Apr, 2042
Active
US7696182 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 16 May, 2025
Active
US8541393 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 02 Nov, 2024
Active
US9339036 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 02 Nov, 2024
Active


Given below is the list of recent legal activities going on the following drug patents of Cormedix.

Activity Date Patent Number
Patent litigations
Patent Term Extension Application under 35 USC 156 Filed 08 Jan, 2024 US7696182
Payment of Maintenance Fee, 8th Yr, Small Entity 04 Oct, 2023 US9339036
Recordation of Patent eGrant 29 Aug, 2023 US11738120
Mail Patent eGrant Notification 29 Aug, 2023 US11738120
Email Notification 29 Aug, 2023 US11738120
Recordation of Patent Grant Mailed 29 Aug, 2023 US11738120
Patent Issue Date Used in PTA Calculation 29 Aug, 2023 US11738120
Patent eGrant Notification 29 Aug, 2023 US11738120
Email Notification 10 Aug, 2023 US11738120
Electronic Review 10 Aug, 2023 US11738120
Issue Notification Mailed 09 Aug, 2023 US11738120
Application Is Considered Ready for Issue 02 Aug, 2023 US11738120
Dispatch to FDC 02 Aug, 2023 US11738120
Printer Rush- No mailing 21 Jul, 2023 US11738120
Pubs Case Remand to TC 18 Jul, 2023 US11738120


Cormedix's Family Patents


Family Patents



Cormedix Drug List

Given below is the complete list of Cormedix's drugs and the patents protecting them.


1. Defencath

Defencath is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11738120 Synthesis of taurolidine, purity profiles and polymorphs 15 Apr, 2042
(17 years from now)
Active
US7696182 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 16 May, 2025
(7 months from now)
Active
US8541393 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 02 Nov, 2024
(23 days from now)
Active
US9339036 Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin 02 Nov, 2024
(23 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defencath's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List